You are here

Cancer Vaccine Disappoints in Melanoma Trial

Immunotherapeutic agent fails to extend disease-free survival (September 5)

An independent analysis of the DERMA trial — a phase III randomized, blinded, placebo-controlled study of the MAGE-A3 cancer immunotherapeutic — has shown that the study did not meet its first co-primary endpoint as it did not significantly extend disease-free survival (DFS) when compared with placebo in the MAGE-A3–positive population.

The study evaluated the efficacy and safety of the MAGE-A3 cancer immunotherapeutic in stage IIIB/C melanoma patients with macroscopic nodal disease whose tumors expressed the MAGE-A3 gene and who had their tumors removed surgically. MAGE-A3 is a tumor-specific antigen that is expressed in a variety of cancers, including melanoma, with no presentation in normal cells. MAGE-A3 is expressed in about 65% of stage III melanomas.

The drug’s developer (GlaxoSmithKline) will continue the DERMA trial until the second co-primary endpoint is assessed. This endpoint — DFS in the gene signature-positive subpopulation — is designed to identify a subset of MAGE-A3–positive patients that may benefit from the treatment. Results from this analysis are expected in 2015.

The same investigational MAGE-A3 cancer immunotherapeutic is being investigated in another phase III study (MAGRIT) in non–small-cell lung cancer (NSCLC) following surgical removal of the primary tumor, with first data anticipated in the first half of 2014.

Source: GSK; September 5, 2013.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs